THAM reduces CO2-associated increase in pulmonary vascular resistance – an experimental study in lung-injured piglets by Staffan Höstman et al.
Höstman et al. Critical Care  (2015) 19:331 
DOI 10.1186/s13054-015-1040-4RESEARCH Open AccessTHAM reduces CO2-associated increase in
pulmonary vascular resistance – an
experimental study in lung-injured piglets
Staffan Höstman1,2* , João Batista Borges1,2,4, Fernando Suarez-Sipmann1,2, Kerstin M. Ahlgren1,2,
Joakim Engström1,2, Göran Hedenstierna1,3 and Anders Larsson1,2Abstract
Introduction: Low tidal volume (VT) ventilation is recommended in patients with acute respiratory distress
syndrome (ARDS). This may increase arterial carbon dioxide tension (PaCO2), decrease pH, and augment pulmonary
vascular resistance (PVR). We hypothesized that Tris(hydroxymethyl)aminomethane (THAM), a pure proton acceptor,
would dampen these effects, preventing the increase in PVR.
Methods: A one-hit injury ARDS model was established by repeated lung lavages in 18 piglets. After ventilation
with VT of 6 ml/kg to maintain normocapnia, VT was reduced to 3 ml/kg to induce hypercapnia. Six animals
received THAM for 1 h, six for 3 h, and six serving as controls received no THAM. In all, the experiment continued
for 6 h. The THAM dosage was calculated to normalize pH and exhibit a lasting effect. Gas exchange, pulmonary,
and systemic hemodynamics were tracked. Inflammatory markers were obtained at the end of the experiment.
Results: In the controls, the decrease in VT from 6 to 3 ml/kg increased PaCO2 from 6.0±0.5 to 13.8±1.5 kPa and
lowered pH from 7.40±0.01 to 7.12±0.06, whereas base excess (BE) remained stable at 2.7±2.3 mEq/L to 3.4±3.2
mEq/L. In the THAM groups, PaCO2 decreased and pH increased above 7.4 during the infusions. After discontinuing
the infusions, PaCO2 increased above the corresponding level of the controls (15.2±1.7 kPa and 22.6±3.3 kPa for 1-h
and 3-h THAM infusions, respectively). Despite a marked increase in BE (13.8±3.5 and 31.2±2.2 for 1-h and 3-h
THAM infusions, respectively), pH became similar to the corresponding levels of the controls. PVR was lower in the
THAM groups (at 6 h, 329±77 dyn∙s/m5 and 255±43 dyn∙s/m5 in the 1-h and 3-h groups, respectively, compared
with 450±141 dyn∙s/m5 in the controls), as were pulmonary arterial pressures.
Conclusions: The pH in the THAM groups was similar to pH in the controls at 6 h, despite a marked increase in BE.
This was due to an increase in PaCO2 after stopping the THAM infusion, possibly by intracellular release of CO2.
Pulmonary arterial pressure and PVR were lower in the THAM-treated animals, indicating that THAM may be an
option to reduce PVR in acute hypercapnia.Introduction
Low tidal volume (VT) ventilation has been shown to re-
duce ventilator-induced lung injury (VILI) and to im-
prove survival in patients with acute respiratory distress
syndrome (ARDS) [1]. In addition, it seems to reduce
the risk of lung complications after surgery in which pa-
tients are under general anesthesia [2]. Therefore, low* Correspondence: staffan.hostman@surgsci.uu.se
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It has been suggested that ventilation with VT even
less than 6 ml/kg would further reduce the risk of VILI
in ARDS [3]. However, very low VT ventilation may in-
crease arterial carbon dioxide tension (PaCO2) substan-
tially. Although hypercapnic acidosis has been shown to
have both negative and positive effects on immune func-
tion, it has unequivocal and clinically relevant negative ef-
fects on the pulmonary circulation, increasing pulmonary
vascular resistance (PVR) [4–7]. This, in combination withle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Höstman et al. Critical Care  (2015) 19:331 Page 2 of 12high positive end-expiratory pressure (PEEP) levels, may
induce acute right heart failure [8, 9].
Different methods to reduce PaCO2 during low VT
ventilation have been suggested, such as reduction of
apparatus dead space by a tracheal double-lumen tube,
tracheal gas insufflation, expiratory flushing of the dead
space by a tracheal catheter, or prolonging the end-
inspiratory pause [10–13]. One of the most common
methods is to increase minute ventilation by increasing re-
spiratory rate (RR). However, this sometimes results in an
unwanted buildup of auto-PEEP. Furthermore, it might be
that the increased RR in itself, owing to increased energy
transfer to the lungs, induces VILI. Indeed, very high RR
combined with very low VT using high-frequency oscilla-
tion has not been shown to be beneficial and might even
increase mortality in ARDS [14, 15].
Other methods are extracorporeal CO2 removal using
an arteriovenous or venovenous approach with a low
blood flow through a small membrane oxygenator/CO2
remover. However, this method has not yet been shown to
improve clinical outcome [16]. Thus, in many situations
with low VT ventilation, hypercapnic acidosis is unavoidable.
Because the acidosis caused by the increased PaCO2
may be the main reason for the side effects of “permis-
sive hypercapnia,” it has been speculated whether treat-
ment with sodium bicarbonate (NaHCO3) would be
useful [1, 17, 18]. In fact, in order for NaHCO3 to work
as a buffer, it has to generate CO2, which in turn has to
be removed via the lungs increasing ventilatory demands
[19]. Because the problem with low VT ventilation is that
the CO2 excretion via the lungs is impaired, NaHCO3 is
theoretically not a good choice for buffering in these
conditions. However, Tris(hydroxymethyl)aminomethane
(THAM), or trometamol, which is a pure proton acceptor
that exerts its buffer effects without generating CO2, could
be a more logical choice in cases of excessive CO2 accu-
mulation [20]. In addition, there are experimental data in-
dicating that THAM may attenuate VILI [21]. THAM has
already been used with success in cases with severe
asthma and as an adjunct in ARDS [5, 20, 22]. However,
in all published studies so far, THAM has been used at a
modest dose, for a short period of time, and not with the
aim of full pH correction. Using a porcine model, we have
previously shown that THAM could be used to correct
pH for at least 3 h during total apnea and that PVR was
not severely increased during this period [23]. The aims of
the present study were to explore how THAM, adminis-
tered during two limited periods of very low VT ventila-
tion, would affect, first, pH and PVR and, second, lung
inflammatory parameters in a porcine lung lavage model.
We hypothesized that, during hypercapnia, THAM infu-
sion would keep pH normal by increasing the metabolic
base component, would prevent increase of PVR, and
would not increase lung injury.Methods
The study was approved by the Animal Research Ethics
Committee at Uppsala University, and the National In-
stitutes of Health guidelines for animal research were
followed. The study was performed at the Hedenstierna
Laboratory, Uppsala University, Uppsala, Sweden.
Anesthesia, ventilation, instrumentation, and monitoring
Eighteen pigs (23.0–30.5 kg body weight) were premedi-
cated with 6 mg kg−1 tiletamine and zolazepam (Zoletil
Forte; Boehringer Ingelheim Vetmedica, Ingelheim,
Germany) and 2.2 mg kg−1 intramuscular xylazine
(Rompun; BayerDVM, Shawnee Mission, KS, USA).
After 5–10 minutes, the animal was placed supine on a
table and a tracheotomy was performed by inserting an
8-mm I.D. endotracheal tube (Mallinckrodt Medical,
Dublin, Ireland). Ventilation was started using a volume-
controlled mode on a SERVO-i ventilator (Maquet Crit-
ical Care, Solna, Sweden) with VT 8 ml kg
−1, inspiratory/
expiratory ratio (I:E) 1:1, fraction of inspired oxygen
(FiO2) 0.5, RR 25 cycles/min, and PEEP 5 cmH2O. Just
before the tracheostomy, a bolus of fentanyl 10–20 μg
kg−1 was given intravenously. Anesthesia was then main-
tained with ketamine 30 mg kg−1 h−1, midazolam 0.1 mg
kg−1 h−1, and fentanyl 4 μg kg−1 h−1. After checking that
anesthesia was sufficient to prevent responses to painful
stimulation between the front toes, muscle relaxation
was added by a continuous infusion of pancuronium 0.3
mg kg−1 h−1.
During the first hour, 10 ml kg−1 h−1 Ringer’s acetate
was infused intravenously, after which the infusion rate
was lowered to 5 ml kg−1 h−1 intravenously. After open
dissection of the neck vessels, an arterial catheter was
inserted into the right carotid artery for blood sampling
and blood pressure monitoring, and a central venous
catheter was inserted via the right external jugular vein.
In addition, a pulmonary arterial catheter (Criti Cath
No7; Ohmeda, Singapore) for measurement of cardiac
output (CO) and pulmonary arterial pressure was intro-
duced via the right external jugular vein, and its correct
position was verified by pressure monitoring. CO was
obtained as the mean of three values measured by ther-
modilution after injection of 10 ml of ice-cold saline into
the central venous catheter (Siemens SC 9000XL; Dräger,
Lübeck, Germany). A bladder catheter was inserted supra-
pubically to measure hourly urine production. Electrocar-
diographic monitoring was started, and peripheral
capillary oxygen saturation was monitored at the base of
the tail by pulse oximetry (Siemens SC 9000XL). Next, a
lung recruitment maneuver was performed with I:E 1:1,
RR 6 breaths/min, pressure control, inspiratory pressure
40 cmH2O, and PEEP 20 cmH2O for 60 seconds. If the
animal was considered hemodynamically unstable (mean
arterial blood pressure [MAP] <50 mmHg) at this point,
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ical, Kista, Sweden) were given until a MAP of at least 50
mmHg was reached. All recruitment maneuvers were
performed in the manner detailed above.Estimation of required amounts of buffer to equilibrate
protons
Using data from a pilot study and previous experiments,
we targeted a pH of 7.35 and a PaCO2 of 15 kPa at the
6-h endpoint. The pH target of 7.35 was chosen because,
as seen in the study by Weber et al. [5], already at pH of
approximately 7.2 there was a rise in mean pulmonary
arterial pressure (MPAP). Inserting these values into the
Henderson-Hasselbalch equation and solving for HCO3
− =
10(7.2−6.1)∙0.23 × 15 = 43 mEq/L, we could find the mEq/L
amount of buffer needed as the difference between this
value and normal bicarbonate (HCO3
−), which was as-
sumed to be 20 mEq/L. The buffering capacity
needed for 1 h of infusion was then estimated as
weight in kilograms × 23 × 0.4 = 9.2 × weight. The recom-
mended dosing for THAM (Addex-THAM; Fresenius
Kabi, Uppsala, Sweden) is normally calculated with a coef-
ficient of 0.3, not 0.4, but in a pilot study a 1h infusion
with coefficient 0.3 was found to be an inadequate dose;
therefore, the coefficient was raised.Experimental protocol
Preparations
After the instrumentation, a lung recruitment maneuver
was performed to homogenize lung volume history, FiO2
was set to 1.0, and the animal was allowed to stabilize
for at least 15 minutes before baseline blood gas values
were recorded; that is, arterial and venous blood was
sampled for measurement of oxygen tension (PaO2),
PaCO2, mixed venous oxygen saturation, hemoglobin,
lactate, sodium, chloride, potassium, calcium, glucose
content, pH, and base excess (BE) (ABL800 FLEX; Radi-
ometer, Copenhagen, Denmark), and oxygen hemoglobin
saturation (OSM3; Radiometer). The following baseline
hemodynamic parameters were measured: MAP, MPAP,
central venous pressure (CVP), pulmonary capillary
wedge pressure, and CO. Brody’s formula [24] for body
surface area of pigs was used for the cardiac index (CI)
calculations. PEEP was set to 0 cmH2O, and an airway
pressure-volume (PV) loop was obtained by slow insuf-
flation to 40 cmH2O followed by slow exsufflation via an
occluder [25], and functional residual capacity was ob-
tained (FRC) using a sulfur hexafluoride washin/washout
method [26, 27].
After baseline measurements, lung injury was induced
by repeated lung lavages with 30 ml/kg of 37–39 °C normal
saline (eight in total). Blood gases were sampled again, and
MAP, MPAP, and CVP, as well as FRC and compliance ofthe respiratory system as obtained from the maximum
slope of the expiratory PV loop, were recorded [25].
Next, the tracheal tube was replaced with a double
lumen endotracheal tube with both distal openings in
the trachea [10]. The inspiratory tubing was connected
to one of the endotracheal tube lumens and the expira-
tory tubing was attached to the other lumen, separating
inspiration from expiration. Thus, the apparatus dead
space was eliminated. A second lung recruitment maneu-
ver was performed, and the ventilator was set to PEEP 10
cmH2O, VT 6 ml/kg, and I:E 1:2, and the RR was adjusted
to target a pH between 7.38 and 7.42 in two successive
blood samples obtained within a 15-minute time window.
Main experiment
After confirming that pH was normal by arterial and
venous blood gas sampling, hemodynamic measure-
ments (time point 0) were registered. Hypoventilation
was initiated by reducing VT to 3 ml/kg, and THAM in-
fusion was started at the same time through a central
venous line, in the two buffering groups. Arterial and
mixed venous blood gases were obtained at 5, 10, 15, 30,
60, 90, and 120 minutes and then every hour up to 6 h
from time point 0. In addition, the hemodynamic vari-
ables were registered at similar time points, except at 5
and 10 minutes.
After 6 h of low VT ventilation, further data were col-
lected by drawing venous samples for cytokine analyses,
measuring FRC and compliance and performing a lavage of
the basal right lung with 30 ml of normal saline. Thereafter
the left lung was removed and dissected to obtain tissue
samples from the ventral, medial, and dorsal parts at the
hilar level. The tissue samples were frozen in liquid nitrogen
and stored at −80 °C. The animals were killed with an intra-
venous dose of potassium chloride under deep anesthesia.
Cytokine analysis
Pieces weighing between 80 and 320 mg were homoge-
nized in lysis buffer (15 mM Tris, pH 7.4, 150 mM NaCl,
1 mM CaCl2, 1 mM MgCl2, 0.5 % Triton X-100), with
addition of protease inhibitor (Thermo Scientific, Waltham,
MA, USA) using an IKA Ultra-Turrax T8 homogenizer
(IKA-Werke, Staufen im Breisgau, Germany). Homoge-
nates were centrifuged at 300×g at 4 °C for 10 minutes.
Supernatants were kept at −80 °C until assay. Cytokine
content was assessed using a DuoSet enzyme-linked im-
munosorbent assay (ELISA) system (R&D Systems, Minne-
apolis, MN, USA), for porcine tumor necrosis factor
(TNF)-α, interleukin (IL)-1β/IL-1F2, and IL-6 according to
the manufacturer’s instructions. The detection limits of the
assays were 125 pg/ml for TNF-α, 62.5 pg/ml for IL-1β/IL-
1F2, and 125 pg/ml for IL-6. Total protein content of the
supernatant was measured using a Coomassie Plus Assay
(Thermo Scientific) according to the manufacturer’s
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malized against total protein content of the homogenate.Statistics
A power analysis (analysis of variance [ANOVA]) indi-
cated that six animals in each group would be enough to
detect a pH difference of 0.1 with a standard deviation
of 0.05 with a p <0.05 and a power of 0.8, assuming a
normal distribution.
If there was a clear resemblance with the exponential
distribution, a log transformation was performed to
improve normality. If the variables did not pass the
Shapiro-Wilk normality test, Kruskal-Wallis one-way
ANOVA was performed. Tukey’s honestly significant dif-
ference was assessed post hoc. The data are presented as
mean and standard deviation. The statistical calculations
were performed using R 3.1.1 [28] and SigmaPlot 11.0
(Systat Software, San Jose, CA, USA).Results
All values reported in groups of three are in the order
controls (NT), 1-h infusion (1T), 3-h infusion (3T) of
THAM. p-Values reported are with regard to NT unless
otherwise specified.Blood gas and acid–base status
Blood gas and acid–base data are reported in Table 1
and graphed in Fig. 1.
As evident in Fig. 1, arterial pH was largely different
between the groups during THAM infusion. These dif-
ferences diminished over time, showing no differences
between groups at 360 minutes. PaCO2 rose in all
groups. At the end of infusions, both the 1T and 3T
groups showed a second phase of PaCO2 increase,
whereas NT changed very little after 120 minutes. There
was a large difference in PaCO2 at 360 minutes (13.8±1.5
kPa vs 15.2±3.3 kPa, p =0.55; 22.6±1.7 kPa, p <0.001). The
difference between mixed venous and arterial carbon di-
oxide tension was lower in both 1T and 3T groups starting
from the 15-minute time point (1.8±0.5 kPa vs 0.8±0.4
kPa, p =0.001; 0.6±0.2 kPa, p <0.001). After the infusion,
the 1T group rebounded to levels similar to that of NT. At
360 minutes, the values were 2.1±0.8 kPa vs 2.2±0.6 kPa
(p =0.96) and 1.0±0.7 kPa (p =0.03). At 360 minutes,
the BE values were 3.4±3.2 mEq/L vs 10.2±2.1 mEq/L
(p =0.002) and 27.8±3.1 mEq/L (p <0.001). HCO3
−
showed an increase similar to that of BE.
Arterial oxygen tension (PaO2) trended toward
decrease and was lower at 360 minutes in the 3T
group (p <0.001) compared with controls and the 1T
group. The 3T group had a higher shunt fraction than
the 1T group at 360 minutes (p =0.03).Hemodynamics
Hemodynamic data are reported in Table 2 and graphed
in Fig. 2.
The MPAP was lower in the 3T and 1T groups from
the 30- and 60-minute time points, respectively, onward;
at 360 minutes, however, only the 3T group was different
from the control animals (25±5 mmHg vs 21±2 mmHg,
p =0.17; 18±2 mmHg, p =0.008). PVR was similar to
MPAP, and the 3T group was still different at 360 mi-
nutes (450±141 dyn∙s/m5 vs 329±77 dyn∙s/m5, p =0.11;
255±43 dyn∙s/m5, p =0.0081). CI exhibited a rising trend
over time in all the groups, with 3T separating from the
rest at 360 minutes (3.5±1.0 L/min/m2 vs 3.8±0.75 L/
min/m2, p =0.42; 5.0±0.57 L/min/m2, p <0.001). MAP
and systemic vascular resistance (SVR) did not differ be-
tween the groups at the examined time points, but SVR
showed a decreasing trend over time in all three groups.
Inflammatory markers
Inflammatory marker data are depicted in Fig. 3.
Because many values were at levels too low to be de-
tected with the ELISA, they are not presented in a table.
Most of the missing (i.e., below the detection limit)
values were in the 1T and 3T groups, indicating that they
might be generally lower than in the controls.
In the tissue samples, there was an effect on the IL-6
concentration (detected by two-way ANOVA) in the
THAM strata, and post hoc analysis showed a p-value
of 0.014 compared with controls, with the 3T group
being higher (11.8±11.7 pg/mgprotein) than the 1T group
(4.5±2.0 pg/mgprotein) and non-significant values found for
the rest (p =0.086 for 3T vs NT and p =0.423 for 1T vs NT).
Two-way ANOVA of the TNF-α and IL-1β concentrations
was not done, owing to many missing values. Kruskal-
Wallis one-way ANOVA on ranks was performed for
every tissue strata, with the missing values set below the
minimum measured values. No differences were detected.
Lung mechanics
Data regarding lung mechanics are provided in Table 3.
FRC and compliance of the respiratory system decreased
with the lavages (p <0.001) but did not differ between the
groups.
Electrolytes
Electrolyte data are reported in Table 4.
Arterial sodium concentration fell during the THAM
infusion in both the 1T and 3T groups, and arterial
potassium concentration increased.
Discussion
This study shows the following results in a porcine lung
lavage model:
Table 1 Arterial acid–base values, arterial and venous oxygenation, oxygen consumption, and venous admixture
Parameter Group Baseline Start 60 min 180 min 360 min
pH NT 7.40 (0.04) 7.40 (0.01) 7.14 (0.03) 7.11 (0.05) 7.12 (0.06)
1T 7.40 (0.05) 7.41 (0.02) 7.34 (0.05)a 7.18 (0.05)a 7.16 (0.07)
3T 7.43 (0.02) 7.40 (0.01) 7.35 (0.02)a 7.39 (0.01)a,b 7.16 (0.03)
PaCO2 (kPa) NT 6.6 (1.2) 6.0 (0.5) 12.3 (1.2) 13.5 (1.4) 13.8 (1.5)
1T 6.0 (0.6) 5.8 (0.3) 10.2 (0.9)a 14.6 (2.4) 15.2 (3.3)
3T 6.3 (0.7) 5.9 (0.7) 10.6 (0.7)a 13.1 (0.5) 22.6 (1.7)a,b
PaO2 (kPa) NT 62.6 (12.7) 63.7 (7.4) 48.1 (12.0) 45.2 (12.3) 46.4 (11.8)
1T 65.2 (4.8) 65.0 (8.6) 59.8 (6.3) 49.4 (9.0) 53.3 (5.0)
3T 55.5 (15.5) 56.0 (4.6) 49.7 (4.1) 32.6 (7.6)§ 30.0 (7.7)a,b
Base excess (mEq/ml) NT 4.8 (2.2) 2.7 (2.3) 1.3 (2.2) 1.8 (2.8) 3.4 (3.2)
1T 3.0 (3.2) 2.4 (1.5) 13.8 (3.5)a 10.9 (3.1)a 10.2 (2.1)a
3T 6.2 (2.1) 2.4 (3.0) 16.0 (0.6)a 31.2 (2.2)a,b 27.8 (3.1)a,b
HCO3
− (mmol/L) NT 28.5 (1.8) 27.2 (2.5) 29.7 (2.2) 30.8 (2.5) 32.3 (2.8)
1T 27.0 (2.8) 26.7 (1.5) 40.1 (3.2)a 39.3 (3.2)a 38.8 (2.5)a
3T 29.8 (1.9) 26.8 (3.1) 42.3 (0.9)a 58.6 (2.2)a,b 57.2 (2.8)a,b
SaO2 (%) NT 98 (0.3) 98 (0.2) 97 (0.4) 97 (0.6) 97 (0.6)
1T 98 (0.2) 98 (0.3) 98 (0.3)a 98 (0.2) 97 (0.2)
3T 98 (0.8) 98 (0.1)c 98 (0.2)a 98 (0.3) 97 (0.8)
SvO2 (%) NT 71 (11) 53 (11) 63 (6.1) 67 (5.8) 67 (11)
1T 68 (4.6) 43 (5.2) 54 (10) 65 (6.5) 66 (10)
3T 70 (7.6) 47 (11)c 61 (7.9) 69 (4.6) 74 (2.1)
VO2 (ml/min) NT 133 (32) 124 (22) 118 (23) 120 (9) 121 (21)
1T 128 (28) 142 (18) 131 (20) 139 (14)c 140 (26)
3T 133 (30)c 123 (18)c 117 (7) 127 (7) 134 (13)
Qs/Qt (fraction) NT 0.15 (0.03) 0.11 (0.04) 0.17 (0.04) 0.20 (0.07) 0.20 (0.08)
1T 0.13 (0.03) 0.09 (0.02) 0.11 (0.03)a 0.17 (0.05)c 0.15 (0.04)
3T 0.16 (0.02)c 0.12 (0.02)c 0.15 (0.03)b 0.24 (0.04) 0.26 (0.06)b
Lactate (mmol/L) NT 1.1 (0.26) 1.3 (0.23) 0.7 (0.08) 0.6 (0.14) 0.6 (0.14)
1T 1.6 (0.81) 1.4 (0.14) 1.1 (0.19)a 0.6 (0.14) 0.7 (0.19)
3T 1.1 (0.32) 1.2 (0.15) 0.9 (0.31) 0.9 (0.23)a 1.3 (0.59)a,b
ΔPaCO2 (kPa) NT 1.5 (0.6) 2.2 (0.6) 1.9 (0.5) 2.2 (0.7) 2.1 (0.8)
1T 1.8 (0.4) 2.6 (0.3) 0.7 (1.1)a 2.1 (0.3) 2.2 (0.6)
3T 1.5 (0.3) 2.7 (0.3) 0.6 (0.4)a 0.2 (0.6)a,b 1.0 (0.7)a,b
Abbreviations: BE arterial base excess, HCO3
− arterial bicarbonate concentration, NT control animals that did not receive THAM, PaCO2 arterial carbon dioxide
tension, ΔPaCO2 arteriovenous difference in carbon dioxide tension, PaO2 arterial oxygen tension, Qs/Qt venous admixture obtained at inspired oxygen fraction
1.0, SvO2 mixed venous oxygen saturation, 1T group that received THAM infusion for 1 h, 3T group that received THAM infusion for 3 h, THAM Tris(hydroxymethyl)
aminomethane, VO2 body oxygen consumption
The time points refer to time after start of THAM infusion or corresponding time points in the controls (NT)
aValue is different from NT group
bValue is different from 1T group
cOnly 5 subjects represented owing to technical error
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effective VT from 6 ml/kg to 3 ml/kg decreased pH
with a slow metabolic compensation during the
study period and increased PVR, but it did not
deteriorate CO or have other severe effects. Thus,these findings indicate that hypercapnia in this
model did not compromise right heart function.
2. Buffering with THAM infused for 1 or 3 h
intravenously immediately normalized pH both by
reducing the increase in PaCO2 and by a fast
Fig. 1 Effects of Tris(hydroxymethyl)aminomethane on arterial pH, base excess, arterial carbon dioxide tension (PCO2) and arteriovenous
difference in PCO2. The graph shows the progression over time, with the x-axes representing time points. Note the offset y-axes. The end of
infusion for the 1-h and 3-h groups are marked with a darkened vertical bar. Values are means, and the error bars represent standard deviations
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decreased PVR.
3. After the end of the continuous infusion of THAM,
there was a rebound increase in PaCO2, and, in spite
of a continued high BE, pH decreased to levels
similar to those of the controls at the end of the
experimental period.
4. Notwithstanding the decrease in pH and marked
increase in PaCO2, PVR remained low.
5. The inflammatory response in the lungs as well as
the lung volumes and lung mechanics were not
markedly different between the THAM groups and
the controls.
We previously showed, in a porcine apneic model, that
a continuous THAM infusion maintained pH at physio-
logically acceptable levels for at least 3 h. PVR was only
slightly increased, despite a marked increase in PaCO2
to a maximum of 30 kPa [23]. In that study, where we
investigated whether THAM could totally replace venti-
lation of the lungs for a longer period, we did notdiscontinue the THAM infusion during the experiment.
In the present study, where we studied whether THAM
could be an adjunct to ventilation, pH decreased after
the THAM infusion was stopped. This was due to a re-
bound increase in PaCO2 that was severe after the pro-
longed THAM infusion. Despite this fact, PVR did not
increase, MPAP remained low, and CO increased.
Most studies of the pulmonary circulatory effects of
hypercapnia have been performed in models with
hypoxia-induced pulmonary vasoconstriction (HPV) in
either intact animals or isolated lung preparations where
vasoconstriction was induced by lowering the inspired
oxygenation concentration [29–33]. This is in contrast
to our lavage model, where we kept PaO2 high by FiO2
1.0 and a lung recruitment maneuver followed by PEEP
10 cmH2O. The other important differences are that, in
most of the other previous studies, hypercapnia was in-
duced by administering CO2 in the breathing gas and
manipulations of the metabolic component were done
by infusion of NaHCO3 or HCl [17, 34, 35]. In the ma-
jority of these studies, researchers found that both
Table 2 Hemodynamics
Parameter Group Baseline Start 60 min 180 min 360 min
MPAP (mmHg) NT 18 (3) 21 (4) 28 (4) 28 (4) 25 (5)
1T 19 (2) 20 (3) 21 (4)a 23 (3)a 21 (2)
3T 14 (2)a,b 18 (2) 19 (2)a 17 (2)a,b 18 (2)a
MAP (mmHg) NT 83 (9) 72 (9) 68 (9) 67 (9) 63 (13)
1T 95 (13) 65 (6) 67 (17) 63 (2) 60 (5)
3T 80 (7) 62 (5) 68 (5) 68 (6) 69 (6)
CI (L/min/m2) NT 3.6 (0.5) 2.4 (0.3) 2.9 (0.3) 3.4 (0.7) 3.5 (1.0)
1T 3.4 (0.7) 2.4 (0.3) 2.8 (0.4) 3.8 (0.7) 3.8 (0.8)
3T 4.2 (1.1) 2.4 (0.4) 3.1 (0.5) 4.2 (0.7) 5.0 (0.6)a,b
PVR (dyn∙s/m5) NT 317 (92) 465 (125) 572 (85) 504 (101) 450 (141)
1T 323 (79) 448 (75) 423 (113)a 373 (65)a 329 (77)
3T 264 (69) 481 (109) 373 (103)a 290 (62)a 255 (43)a
SVR (dyn∙s/m5) NT 2240 (515) 2757 (736) 2030 (257) 1720 (297) 1566 (262)
1T 2942 (1201) 2485 (619) 2136 (782) 1517 (283) 1431 (255)
3T 2147 (716) 2558 (250) 2204 (208) 1725 (276) 1449 (125)
Abbreviations: CI cardiac index, MAP mean systemic arterial pressure, MPAP mean pulmonary arterial pressure, NT control animals that did not receive THAM, PVR
pulmonary vascular resistance, SVR systemic vascular resistance, 1T group that received THAM infusion for 1 h, 3T group that received THAM infusion for 3 h,
THAM Tris(hydroxymethyl)aminomethane
The time points refer to time after start of THAM infusion or corresponding time points in the controls (NT)
Values are mean (standard deviation)
aValue is different from NT group
bValue is different from 1T group
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that alkalosis, independent of whether it was metabolic
or hypercapnic, reduced or normalized pulmonary vas-
cular tone. Thus, the pH change in itself was interpreted
to be the main mechanism of this effect [29, 36, 37].
Our results challenge this interpretation because PVR in
the THAM groups was low despite development of a
moderate to severe respiratory acidosis after the THAM
infusion was stopped. Instead, BE and HCO3
− were main-
tained at high levels, indicating that the metabolic com-
ponent might be more important than pH alone in the
regulation of pulmonary vascular tone. That THAM
reduces increases in MPAP caused by hypercapnia has
previously been demonstrated by Weber et al. [5]. How-
ever, they did not find any significant change in PVR
induced by THAM, probably owing to simultaneous
administration of cardiovascular active agents. Further-
more, they did not report any remaining metabolic effect
induced by THAM after the infusion was ended.
In contrast to the pulmonary circulation, we did not
find any relation between arterial BE or pH and vascular
resistance in the systemic circulation. However, the re-
duction in SVR mirrored the increase in PaCO2, suggest-
ing that, in the systemic circulation, PaCO2 per se
influences the vascular tone more than BE or pH does,
confirming results in previous studies [34, 38]. Although
the underlying mechanism of the effect on the vascula-
ture by respiratory or metabolic acid–base changes havenot been fully elucidated, it has been suggested that
intracellular pH changes may regulate the voltage-gated
potassium channels and that this effect is different
between the pulmonary and systemic vessels [39]. Thus, a
decrease in the intracellular pH dilates systemic vessels
and constricts pulmonary vessels. In addition, on the basis
of our present study, we cannot exclude a direct pharma-
cological effect of THAM on the vascular smooth mus-
cles. In agreement with clinical studies, the decrease in
SVR caused by THAM was associated with an increase in
CO and mixed venous oxygen saturation [5].
The significant increase in PaCO2 after THAM infusion
was completed in the THAM-treated animals compared
with the controls was unexpected and, to our knowledge,
has not been described before. The two THAM dosages
were calculated to increase BE to balance the increased
CO2 to keep pH normal. We assumed that PaCO2 would
level out at a new high steady state similar to the controls
when the CO2 excretion via the lungs would again
equalize the CO2 production in the tissues. In the control
animals, this new, higher steady state (at PaCO2 around
15 kPa) occurred after about 120 minutes. However, in the
THAM-treated animals, PaCO2 showed a two-phase
course. During the infusion, the increase in PaCO2
followed, but, as expected, below the increase in PaCO2 of
the controls because THAM reduces the CO2 content in
the blood by catching protons, moving the Henderson-
Hasselbalch equation to the right. However, after the
Fig. 2 Effects of Tris(hydroxymethyl)aminomethane on hemodynamics. The graph shows the progression over time, with the x-axes representing
time points. Note the offset y-axes. The end of infusion for the 1-h and 3-h groups is marked with a darkened vertical bar. Values are means, and
the represent standard deviations. SVR systemic vascular resistance
Höstman et al. Critical Care  (2015) 19:331 Page 8 of 12infusion was stopped, PaCO2 increased and leveled off at
a higher level than in the controls. In the animals treated
with THAM for 3 h, the PaCO2 increase was substantial,
from a mean of 15 to 23 kPa with no clear steady state at
the end of the experiment.
Three theoretical mechanisms might explain the
increased PaCO2 after the THAM infusion was stopped:
1. Reduced alveolar ventilation: However, the tidal
volumes were kept constant throughout the study,
and we do not have any indications in any of the
groups that physiological dead space increased or
that a marked increase in pulmonary shunt occurred
after the end of the infusion.
2. Increased metabolism: However, body temperature
was kept constant, and calculated oxygen
consumption was unchanged; therefore, it is not
plausible that CO2 production increased.
3. Increased CO2 accumulation in the tissues due to
reduced pulmonary excretion during the THAM
infusion: This is indicated by the significantly lowerpulmonary mixed venous-arterial PaCO2 gradient
value during the THAM infusion in the 3-h THAM
group. Thus, THAM might have sequestered CO2
that thereafter accumulated in the tissues. Because
the tension of CO2 cannot be higher in the tissues
than in the blood, the CO2 must have been stored as
HCO3
−, probably in the intracellular compartment.
However, THAM penetrates slowly into the intracel-
lular compartment, and during the first hour most
of the protonated THAM was probably excreted via
the kidneys [19]. This can explain why we found
only a minor (non-significant) increase in PaCO2
after the infusion in the 1-h THAM infusion group,
in contrast to the marked increase in the 3-h infu-
sion group. Thus, one could speculate that the intra-
cellular concentration of CO2, stored as HCO3
−
together with protonated THAM, might have been
very high at the end of the infusion in the 3-h group.
When the infusion was stopped, the intracellular
HCO3
− was, via the effect of carbonic anhydrase, trans-
formed into CO2, which penetrated the cell membranes
Fig. 3 Standard box-and-whisker plots of the cytokine levels stratified by amount of Tris(hydroxymethyl)aminomethane (THAM) given. Note that
the two top panels depict tumor necrosis factor (TNF)-α in bronchoalveolar lavage fluid and interleukin (IL)-6 in plasma. CD dorsal, CM medial,
CV ventral
Table 3 Lung mechanics
Parameter Group Baseline Lung lavage End
FRC (ml) NT 386 (45) 224 (81) 278 (46)
1T 435 (105) 231 (54) 287 (116)
3T 341 (53) 158 (21) 202 (46)
Cexp (ml/cmH2O) NT 47 (10) 37 (9) 47 (5)
1T 51 (19) 39 (17) 49 (17)
3T 51 (7) 41 (2) 50 (3)
Abbreviations: Cexp compliance of the respiratory system obtained as the
maximal slope of a full expiratory pressure-volume curve, FRC functional re-
sidual capacity, NT control animals that did not receive Tris(hydroxymethyl)
aminomethane (THAM), 1T group that received THAM infusion for 1 h, 3T
group that received THAM infusion for 3 h
Lung lavage values obtained 30 minutes after lung lavage; end values
obtained at the end of the experiment
Values are mean (standard deviation)
Höstman et al. Critical Care  (2015) 19:331 Page 9 of 12easily and increased PaCO2. Nevertheless, this unex-
pected effect of THAM needs further exploration.
THAM can have important side effects, such as
hypoglycemia, hyperkalemia, and hypotension [19]. In
this study, although potassium levels increased, glucose
levels were normal and blood pressure was maintained.
We did not find any major differences in inflammatory
markers between the groups. Only IL-6 showed a signifi-
cant increase in lung tissue, whereas we could not find
any difference in TNF-α or IL-1β. The time with acidosis
was significantly less in the THAM groups, which in-
dicates that, when very low VT ventilation in addition
to adequate PEEP level are used, the potential specific
anti-inflammatory effect of hypercapnic acidosis is
minor and that THAM is probably safe to administer
in this regard. This notion is further strengthened by
the fact that lung mechanics and FRC recovered to a
similar degree after lavage in all groups. Our findings
are in accord with those reported by Caples et al.,
who found that buffering with THAM ameliorated
Table 4 Electrolytes
Parameter Group Start 60 min 180 min 360 min
[Na+] (mmol/L) NT 134 (1) 134 (1) 132 (2) 130 (2)
1T 134 (2) 129 (2)a 134 (1) 135 (1)a
3T 132 (2)a,b 125 (2)a,b 125 (2)a,b 138 (3)a,b
[K+] (mmol/L) NT 4.3 (0.2) 4.6 (0.2) 5.2 (0.4) 5.5 (0.6)
1T 4.5 (0.2) 5.1 (0.3)a 5.0 (0.3) 5.2 (0.4)
3T 4.3 (0.3) 5.0 (0.3) 5.9 (0.3)a,b 4.8 (0.5)
[Ca2+] (mmol/L) NT 1.43 (0.17) 1.51 (0.16) 1.35 (0.11) 1.29 (0.11)
1T 1.43 (0.14) 1.33 (0.19)a 1.36 (0.14) 1.28 (0.13)
3T 1.25 (0.06)b 1.21 (0.04)a 1.01 (0.06)a,b 1.09 (0.05)a,b
[Cl−] (mmol/L) NT 101 (2) 99 (1) 98 (2) 93 (3)
1T 101 (1) 98 (1) 97 (3) 93 (2)
3T 104 (3) 99 (1) 96 (2) 94 (2)
Abbreviations: [Ca2+] arterial calcium concentration, [Cl−] arterial chloride concentration, [K+] arterial potassium concentration, [Na+] arterial sodium concentration,
NT control animals that did not receive THAM, 1T group that received THAM infusion for 1 h, 3T group that received THAM infusion for 3 h,
THAM Tris(hydroxymethyl)aminomethane
The time points refer to time after start of THAM infusion or corresponding time points in the controls (NT)
Values are mean (standard deviation)
aValue is different from NT group
bValue is different from 1T group
Höstman et al. Critical Care  (2015) 19:331 Page 10 of 12ventilation-induced lung cell injuries in isolated rat
lungs [21].
The possible clinical implication of our study is that
THAM might be useful in cases of high PVR complicat-
ing permissive hypercapnia by reducing the pulmonary
vascular tone. However, this has to be done very cau-
tiously, particularly because the mechanism of the re-
bound effect of PaCO2 is unknown. Thus, the dose and
infusion time should be restricted, and PaCO2 and potas-
sium levels should be carefully monitored, as should
PaO2, which might decrease owing to inhibition of HPV.
This study has the following inherent limitations of all
animal models, and the results cannot be assumed to be
fully valid in patients:
1. Although pigs have physiology very similar to that of
as humans, their immunologic responses, as well as
their response to THAM, might be different from
those of humans.
2. The effect on the pulmonary vasculature might be
more prominent in pigs because pigs have a strong
HPV [40].
3. We used an open lung approach, the animals were
never hypoxemic, and inhibition of HPV may
deteriorate oxygenation importantly in ARDS [37].
4. We used FiO2 1.0, which might have augmented the
pulmonary vasodilatory effect associated with
THAM.
5. Although THAM was infused in a large vein, its
high osmolality may have caused endothelial
damage. However, the osmolality is less than the
commonly used concentration of hypertonic salineand amino acid solutions used for parenteral
nutrition.
6. Possible toxic side effects were not addressed.
7. The number of animals used, as well as the
observation period, was limited.
Conclusions
This experimental study of permissive hypercapnia in a
porcine lung lavage model shows that intravenous infu-
sion of THAM increased BE and bicarbonate concentra-
tion, normalized pH, and decreased PaCO2 during the
infusion. After a prolonged infusion, however, pH
decreased to values similar to those in controls owing to
a rebound PaCO2 increase. Despite a similar low pH and
a higher PaCO2 compared with controls, the PVR
remained low in the THAM group. No major signs of
augmentation of lung injury by THAM were found.
These findings suggest that CO2 removal from the lungs
is hampered during THAM infusion and that the meta-
bolic component (i.e., BE, bicarbonate) has an important
influence on the pulmonary vascular tone, indicating the
potential use of THAM in situations with hypercapnia-
induced pulmonary hypertension and increased PVR.
Key messages
 Increased pulmonary vascular resistance caused by
respiratory acidosis was countered with THAM.
 After a high-dose infusion of THAM, PaCO2
rebounded to a higher-than-expected level.
 THAM did not importantly affect the inflammatory
response.
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